HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Reliant Technologies, Inc., "the pioneer of fractional resurfacing and market leader of aesthetic laser skin treatments," announced its distinction as nation's 157 fastest growing company out of 500 companies by Inc. magazine, according to August 21 release. Inc. magazine also named Reliant fifth in top 50 businesses in Silicon Valley and eighth among top U.S. health companies. In 2004, Reliant Technologies introduced Fraxel platform of lasers, "the most advanced skin resurfacing systems available for dermatologists and cosmetic surgeons," says release. Sales of Fraxel laser systems contributed to company's $70.5 million revenue in 2007, a 1,450 percent increase since 2004. Eric Stang, CEO and president of Reliant Technologies, says that Fraxel brand has become "the gold standard in laser skin resurfacing preferred by physicians and patients alike." The firm recently announced a partnership with electronics giant Philips to develop laser skin-rejuvenation technology for at-home use (1"The Rose Sheet" August 18, 2008, p. 5)

You may also be interested in...

Reliant Links With Philips To Develop Laser Skin-Care Device For Home Use

Reliant Technologies Inc., developer of Fraxel laser systems, has partnered with electronics giant Philips to develop laser skin-rejuvenation technology for use at home, taking a cue from some of the industry's biggest players that are making moves toward the aesthetic devices market

Recordati Raises Forecast for Isturisa After Smooth Launches

The Italian firm's move to license Isturisa from Novartis last year is paying dividends already and Recordati has already tripled its peak sales forecast for the Cushing's therapy.

Progress In Pharma’s Slow Battle Against A Deadly Infant Virus

Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts